Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis.
Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy.
Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.
Mosaic Subventricular Origins of Forebrain Oligodendrogenesis.
Risk of multiple sclerosis after a first demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological features and application of the McDonald 2010 MRI criteria.
Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS).
Complex I Subunit Gene Therapy with NDUFA6 Ameliorates Neurodegeneration in EAE.
Randomized trial of erhuangfang for relapsing multiple sclerosis.
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.
Brain functional plasticity at rest and during action in multiple sclerosis patients.
Exacerbation of experimental autoimmune encephalomyelitis in mice deficient for DCIR, an inhibitory C-type lectin receptor.
Mitochondrial DNA T4216C and A4917G variations in multiple sclerosis.
[Familial amyloidotic polyneuropathies].
Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.
Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience.
Altered expression of myelin-associated inhibitors and their receptors after traumatic brain injury in the mouse.
Distinct T cell signatures define subsets of patients with multiple sclerosis.
Masquerades of Acquired Demyelination in Children: Experiences of a National Demyelinating Disease Program.
"History had taken such a large piece out of my life" - Neuroscientist refugees from Hamburg during National Socialism.
Characteristics, diagnosis and outcome of patients referred to a specialized neurology emergency clinic: prospective observational study.
Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation.
Generic quality of life burden of multiple sclerosis as compared to other debilitating chronic conditions.
Functional Relapses in Pediatric Multiple Sclerosis.
TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress.
Pages
« first
‹ previous
…
620
621
622
623
624
625
626
627
628
…
next ›
last »